BioCryst Pharmaceuticals | BCRX - 贷款资金



金融业
股票价格
USD
资产
USD 465.05M
现金及等价物
USD 171.59M
销售成本
USD 9.52M
流动资产
USD 373.63M
流动负债
USD 195.39M
债务
USD 828.6M
股息收益率
0
EBIT
USD 260.39M
EBITDA
USD 51.7M
员工
536
EPS每股收益
USD 1.17
股本和储备
USD -553.84M
销售毛利
USD 153.05M
债务利息支出
USD 14.14M
利息收入
USD -0.13
贷款资金
USD 395.2M
市值
USD 1.88B
净收入
USD 245.85M
营业费用
USD -553.84M
营业利润
USD 260.39M
普通股股本
USD 213.06M
PE价格收益
6.06
税前利润
USD 248.02M
销售收入
USD 406.56M
销售和管理费用
USD 95.78M
股票
USD 5.99M
贸易债权人
USD 10.96M
应收帐款人
USD 106.82M


贷款资金 更改 日
Alnylam Pharmaceuticals USD 2.48B 931K 2026-03
BioCryst Pharmaceuticals USD 395.2M 33.48M 2026-03
Chugai Pharma JPY 4.53B 1.95B 2024-12
Daiichi Sankyo JPY 300.15B 199.41B 2025-12
DBV Technologies USD 0 0 2025-03
Enanta Pharmaceuticals USD 0 0 2024-12
Gilead Sciences USD 20.86B 1.27B 2026-03
GlaxoSmithKline GBP 14.01B 696M 2026-03
Glaxosmithkline GBP 19.82B 203.13M 2025-12
Incyte USD 29.41M 785K 2026-03
Ionis Pharmaceuticals USD 1.91B 9M 2026-03
Karyopharm Therapeutics USD 278.22M 278.22M 2025-12
Neurocrine Biosciences USD 169.5M 500K 2023-03
Novavax USD 246.3M 200K 2025-12
PTC Therapeutics USD 286.94M 1.74B 2026-03
Regeneron Pharmaceuticals USD 1.99B 719.7M 2026-03
Roche Holding CHF 27.43B 966M 2025-12
Sarepta Therapeutics USD 838.16M 9.19M 2026-03
Ultragenyx Pharmaceutical USD 1.13B 19M 2026-03
Vertex Pharmaceuticals USD 106.7M 4.7M 2025-12